ApprovedFDA approval

Loargys (pegzilarginase-nbln)

Immedica Pharma

Marketer take

An enzyme therapy for Arginase 1 deficiency used alongside protein restriction, so metabolic geneticists and dietitians are the core audience, and newborn screening and specialist centers drive patient finding.

Sponsor company
Immedica Pharma
Indication
To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction
Therapeutic area
Rare disease, Metabolic
Event
FDA approval
Date
Feb 23, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move